SUTRO BIOPHARMA, INC. (STRO)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenue | 63,745 | 17,399 | 8,520 | |
| Restructuring and related costs | 18,422 | - | - | |
| Research and development | 38,325 | - | 62,108 | |
| General and administrative | 10,343 | - | 14,331 | |
| Total operating expenses | 67,090 | 85,913 | 76,439 | |
| Loss from operations | -3,345 | -68,514 | -67,919 | |
| Interest income | 2,519 | 3,189 | 4,875 | |
| Unrealized gain on equity securities | - | - | - | |
| Non-cash interest expense related to the sale of future royalties | 9,647 | 9,344 | 7,910 | |
| Interest and other income (expense), net | -1,044 | -1,299 | 22,167 | |
| Loss before provision for income taxes | -11,517 | - | -48,787 | |
| (benefit) from / provision for income taxes | -18 | - | - | |
| Net loss | -11,499 | -75,968 | -48,787 | |
| Net loss per share, basic | -0.14 | -0.91 | -0.59 | |
| Net loss per share, diluted | -0.14 | -0.91 | -0.59 | |
| Weighted average number of shares outstanding, basic, total | 84,580,125 | 83,106,013 | 82,043,671 | |
| Weighted-average shares used to compute diluted eps | 84,580,125 | 83,106,013 | 82,043,671 | |